Strikingly, the combinatorial treatment also showed activity against cells originating from refractory GCB and non-GCB DLBCL patients, indicating that dual mTOR and PI3Kβ/δ inhibition might represent a promising novel strategy to target tumor cells resistant to first-line therapy. This evidence concerns the gene MTOR and diffuse large B-cell lymphoma.